Filing Details
- Accession Number:
- 0001219036-21-000014
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-07-08 17:50:44
- Reporting Period:
- 2021-07-07
- Accepted Time:
- 2021-07-08 17:50:44
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
899923 | Myriad Genetics Inc | MYGN | In Vitro & In Vivo Diagnostic Substances (2835) | 870494517 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1219036 | S Jerry Lanchbury | 320 Wakara Way Salt Lake City UT 84108 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-07-07 | 30,424 | $26.49 | 262,974 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-07-07 | 30,424 | $32.29 | 232,550 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-07-07 | 1,884 | $26.49 | 234,434 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-07-07 | 1,884 | $31.99 | 232,550 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Incentive Stock Option (right to buy) | Disposition | 2021-07-07 | 1,884 | $0.00 | 1,884 | $26.49 |
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-07-07 | 30,424 | $0.00 | 30,424 | $26.49 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2021-09-17 | No | 4 | M | Direct | |
141,828 | 2021-09-17 | No | 4 | M | Direct |
Footnotes
- The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- The shares subject to this option are fully vested and exercisable.